• Bemelman, F.J., Buysmann, S., Surachno, J., Wilmink, J.M., Schellekens, P.T., Ten Berge, I. (1994) Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. Kidney International, 46, 16741679.
  • Buysmann, S., Hack, C.E., Van Diepen, F., Surachno, J., Ten Berge, I. (1997) Administration of OKT3 as a two-hour infusion attenuates first-dose side effects. Transplantation, 64, 16201623.
  • Byrd, J.C., Grever, M., Davis, B., Lucas, M., Park, K., Goodrich, A., Morrison, C., Murphy, T., Kunkel, L., Grillo-Lopez, A., Waselenko, J.K., Foon, K.A. (1999a) PhaseI/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a feasible and active regimen [abstract]. Blood, 94, 3114a.
  • Byrd, J.C., Waselenko, J.K., Maneatis, T.J., Murphy, T., Ward, F.T., Monahan, B.P., Sipe, M.A., Donegan, S., White, C.A. (1999b) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. Journal of Clinical Oncology, 17, 791795.
  • Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V. (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine, 6, 443446.
  • Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J.A., Capdeville, R., Diehl, V., Reyes, F. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood, 92, 19271932.
  • Davis, T.A., White, C.A., Grillo-López, A., Velasquez, W.S., Link, B., Maloney, D.G., Dillman, R.O., Williams, M.E., Mohrbacher, A., Weaver, R., Dowden, S., Levy, R. (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. Journal of Clinical Oncology, 17, 18511857.
  • Emmerich, B., Huhn, D., Peschel, C., Wilhelm, M., Von Schilling, C., Bentz, M., Hallek, M., Knauf, B., Kuse, R., Ho, A. (1999) Treatment of chronic lymphocytic leukemia (CLL) with the anti-CD20 antibody rituximab [abstract]. Blood, 94, 4608a.
  • Faye, A., Quartier, P., Lutz, P., Garbag-Chenon, A., Mathieu-Boue, A., Fisher, A., Vilmer, E. (1999) Anti-CD20 monoclonal antibody in the treatment of post-transplant lymphoproliferative disorders (PLTD) occurring after bone marrow transplantation (BMT) in children [abstract]. Blood, 94, 2842a.
  • Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., Tedesco, F., Rambaldi, A., Introna, M. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 95, 39003908.
  • Hack, C.E., Ogilvie, A.C., Eisele, B., Eerenberg, A.J., Wagstaff, J., Thijs, L.G. (1993) C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Medicine, 19, S19S28.
  • Harjunpaa, A., Junnikkala, S., Meri, S. (2000) Rituximab (Anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian Journal of Immunology, 51, 634641.DOI: 10.1046/j.1365-3083.2000.00745.x
  • IDEC Pharmaceuticals Corporation (1997) Investigational Drug Brochure Rituximab (RituxanTM, Mab Thera, IDEC-C2B8) edition 4, IDEC Pharmaceuticals Corporation, San Diego, CA, USA.
  • IDEC Pharmaceuticals Corporation & Genentech Corporation (1999) USA Package Insert, revised July 1999, IDEC Pharmaceuticals Corp. & Genentech Corp., San Diego, CA, USA.
  • Jansen, N.J., Van Oeveren, W., Van Vliet, M., Stoutenbeek, C.P., Eysman, L., Wildevuur, C.R. (1991) The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. European Journal of Cardiothoracic Surgery, 5, 211217.
  • Jensen, M., Winkler, U., Manzke, O., Diehl, V., Engert, A. (1998) Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC- C2B8, rituximab). Annals of Hematology, 77, 8991.DOI: 10.1007/s002770050419
  • Kleinman, M., Kaplan, E., Rhoades, D., Zats, S., Wechsler, J. (1999) Sargramostim/rituximab therapy for B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) patients: a toxicity profile [abstract]. Blood, 94, 4389a.
  • Van Der Kolk, L.E., Grillo-López, A., Gerritsen, W., Baars, J.W., Van Oers, M.H.J. (1998) Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: a phase I/II clinical trial [abstract]. Blood, 92, 4037a.
  • McLaughlin, P., Grillo-López, A., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D., Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 28252833.
  • Milpied, N., Vasseur, B., Antoine, C., Bouscary, D., Carret, A., Faye, A., Quartier, P., Bourbigot, D., Bourquard, P., Hurault de Ligny, B., Reguerre, Y., Stoppa, A., Parquet, N., Dubief, F., Mathieu-Boue, A., Leblond, V. (1999) Chimeric anti CD20 monoclonal antibody (rituximab) in B post-transplant lympho-proliferative disorders (B-PLTDs): a retrospective analysis on 32 patients [abstract]. Blood, 94, 2803a.
  • Raasveld, M.H., Bemelman, F.J., Schellekens, P.T., Van Diepen, F., Van Dongen, A., Van Royen, E., Hack, C.E., Ten Berge, I. (1993) Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney International, 43, 11401149.
  • Schwaner, I., Von Engelhardt, L., Jordanova, M., Schrewe, M., Gerecke, C., Pinkert, E., Serke, S., Huhn, D. (2000) Rituximab-induced complement cascade activation is related to adverse events and bone marrow involvement [abstract]. Blood, 96, 2181a.
  • Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., Engert, A. (1999a) Cytokine–release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood, 94, 22172224.
  • Winkler, U., Schulz, H., Klein, T., Jensen, M., Manzke, O., Schmitz, S., Rudiger, T., Muller-Hermelink, K., Diehl, V., Engert, A. (1999b) Treatment of patients with mantle-cell and aggressive B-cell non-Hodgkin's lymphoma using the monoclonal anti-CD20 antibody rituximab (Rituxan TM): evaluation of safety and response [abstract]. Blood, 94, 4419a.
  • Winkler, U., Schulz, H., Jensen, M., Manzke, O., Rudiger, T., Muller-Hermelink, K., Diehl, V., Engert, A. (1999c) Toxicity and efficacy of the anti-CD20 antibody rituximab (Rituxan TM) in patients with B-cell chronic lymphocytic leukemia: a phaseI/II study [abstract]. Blood, 94, 1396a.
  • Wolbink, G.J., Bollen, J., Ten Baars, J.W.B.R., Swaak, A.J., Paardekooper, J., Hack, C.E. (1993) Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. Journal of Immunological Methods, 163, 6776.